Skip Navigation


Annals of Oncology Advance Access originally published online on September 26, 2008
Annals of Oncology 2008 19(12):2090-2091; doi:10.1093/annonc/mdn648
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
19/12/2090    most recent
mdn648v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Gajda, M.
Right arrow Articles by Pachmann, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gajda, M.
Right arrow Articles by Pachmann, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

letters to the editor

Monitoring circulating epithelial tumor cells (CETCs) during primary systemic chemotherapy including trastuzumab for early prediction of outcome in patients with Her2/neu-positive tumors

The first 10% of the full text of this article appears below.

In Her2/neu growth factor overexpressing poor prognosis breast cancers trastuzumab has shown to improve disease-free survival as well as overall survival in metastatic and primary diseases. On the basis of these positive results, trastuzumab has also been included into studies of neo-adjuvant therapy of Her2/neu-positive T2 tumors [1].

In our previous report on neo-adjuvant treatment, the initial reduction in circulating epithelial tumor cells (CETC) highly correlated to tumor size reduction [. . . [Full Text of this Article]

M. Gajda1, O. Camara2, S. Oppel3, T. Kroll3, C. Jörke3, S. Krauspe2, U. Hammer3, C. Rabenstein4, M. Untch5, I. B. Runnebaum2 and K. Pachmann3,*

1 Institute of Pathology
2 Women's Hospital
3 Clinic for Internal Medicine II, Friedrich Schiller University, Jena
4 Transfusionsmedizinisches Zentrum Bayreuth, Bayreuth
5 Women's Hospital, HELIOS Klinikum Berlin-Buch, Berlin, Germany

* (E-mail: katharina.pachmann@med.uni-jena.de)


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?